AlzChem Group Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

AlzChem Group wird ein jährliches Gewinn- und Umsatzwachstum von 9.4% bzw. 4.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.2% betragen.

Wichtige Informationen

9.6%

Wachstumsrate der Gewinne

9.6%

EPS-Wachstumsrate

Chemicals Gewinnwachstum38.8%
Wachstumsrate der Einnahmen5.0%
Zukünftige Eigenkapitalrendite23.5%
Analystenabdeckung

Low

Zuletzt aktualisiert20 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Nov 01
Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

Oct 12
Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

May 06
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 05
AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

Mar 04
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

Apr 24
AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

Feb 27
AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 23
AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

Jun 10
Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

Apr 07
At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

Mar 23
AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 10
AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 24
Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Feb 11
Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year

Aug 07
Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Jul 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?

Jul 03
Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?

Gewinn- und Umsatzwachstumsprognosen

XTRA:ACT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20266295931874
12/31/20256005525794
12/31/20245675045794
6/30/2024557467297N/A
3/31/2024546397396N/A
12/31/2023546355273N/A
9/30/2023528301755N/A
6/30/2023549281553N/A
3/31/202357030-1512N/A
12/31/202255030-33-4N/A
9/30/202253429-254N/A
6/30/202248728-280N/A
3/31/202245427329N/A
12/31/2021429281443N/A
9/30/2021420271140N/A
6/30/2021406263463N/A
3/31/2021397231448N/A
12/31/2020386202049N/A
9/30/2020370161052N/A
6/30/2020389171153N/A
3/31/2020387172054N/A
12/31/201938518244N/A
9/30/201938919242N/A
6/30/201938018-1822N/A
3/31/201938020-2033N/A
12/31/201838323-535N/A
9/30/2018380221224N/A
6/30/201839832-131N/A
3/31/201836421N/A23N/A
12/31/201736120N/A31N/A
9/30/201735622N/A31N/A
12/31/201633315N/A33N/A
9/30/201633112N/A39N/A
12/31/201532915N/A30N/A
12/31/201429814N/A18N/A
12/31/201330217N/A16N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACTDas prognostizierte Gewinnwachstum (9.4% pro Jahr) liegt über der Sparquote (0.7%).

Ertrag vs. Markt: ACTDie Erträge des Unternehmens (9.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt German (18.6% pro Jahr).

Hohe Wachstumserträge: ACTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ACTDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: ACTDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ACTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.2%)


Wachstumsunternehmen entdecken